A Phase 3 interventional study of vaccine-13vPnC and vaccine-13vPnC in Pneumococcal Infections, sponsored by Pfizer. Completed at 4 sites in Mexico. Open to participants aged 50 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-01-25.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections — none open to participants now, 1 under way, none of them phase 3. 13-valent pneumococcal vaccine · Pneumococcal Infections.
Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, this one is the 23rd largest by enrollment, is one of 3 that started in 2011, is one of 19 in phase 3, and was the 14th registered.
298 studies on the registry are indexed under Pneumococcal Infections; 25 are open to participants now.
Browse Pneumococcal Infections studies →None of the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections is open now. The open studies under Pneumococcal Infections, anywhere →
13-valent pneumococcal vaccine: first FDA approval 2010 (Prevnar 13). What it is approved for, and how studies give it, is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 50 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 20 · Phase 4 11
First in 2004; this study’s year is marked. 3 started in 2011.
This study's enrollment of 324 is below the median of 373 across 253 interventional studies indexed under Pneumococcal Infections.
Median enrollment 328 across the 44 interventional studies. Of the 40 that completed or were terminated, 23 (57%) have results posted.
This tab as a report to print or save as PDF → With an account.
26 of 44 have an industry lead sponsor. The 10 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
75 studies in Pneumococcal Infections by Pfizer: 4 open now, 8 under way, 5 of them phase 3. Of 67 finished, 45 (67%) have results posted.
Among the 75 studies in Pneumococcal Infections by Pfizer, this one is the 44th largest by enrollment of the 57 interventional ones that give a count, is one of 5 that started in 2011, is one of 33 in phase 3, and was the 30th registered.
Pfizer’s Pneumococcal Infections studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing 13-valent pneumococcal vaccine in Pneumococcal Infections, from their registry updates:
Among Pfizer’s 75 in Pneumococcal Infections:
This tab as a report to print or save as PDF → With an account.
The purpose of this study will be to assess the safety, tolerability, and immunogenicity of 13-Valent Pneumococcal Conjugate Vaccine (13vPnC) when given to healthy adults older than 50 years of age who haven't received 23-valent pneumococcal polysaccharide vaccine in Mexico.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
=\> 65 years of age
Biological: vaccine-13vPnC
50 to 64 years of age
Biological: vaccine-13vPnC
Single dose of 0.5 ml of 13vPnC administered in deltoid muscle of arm at visit 1 (day 1)
Also known as: 13-valent pneumococcal conjugate vaccine
Single dose of 0.5 ml of 13vPnC administered in deltoid muscle of arm at visit 1 (day 1)
Also known as: 13-valent pneumococcal conjugate vaccine
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Titers (GMTs) 1 Month After Vaccination
Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using a quantitative functional OPA assay. Confidence intervals (CIs) for GMT are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers. Individual OPA assay values below the assay LLOQ (lower limit of quantification) were set at a titer of 0.5\*limit of detection (LOD \[8\]) = (titer of 4) for the purpose of calculating the OPA GMT.
Time frame: One month (28 to 42 days) after vaccination
Percentage of Participants Reporting Pre-Specified Local Reactions Within 14 Days After Vaccination
Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present), Mild (2.5 to 5.0 centimeters \[cm\]), Moderate (5.1 to 10.0 cm), Severe (\>10 cm). Pain at injection site scaled as Any (pain present), Mild (does not interfere with activity), Moderate (interferes with activity), Severe (prevents daily activity).
Time frame: Within 14 days after vaccination
Percentage of Participants Reporting Pre-Specified Systemic Events Within 14 Days After Vaccination
Systemic events reported using electronic diary. Fever-Any:\>=38 degrees Celsius (C), Mild (M):\>=38 to \<38.5 degrees C, Moderate(Mod):\>=38.5 to \<39 degrees C, Severe (S):\>=39 to \<=40 degrees C, Potentially life threatening:\>40 degrees C. Headache, fatigue, muscle pain, joint pain- Any: present, M:did not interfere with activity, Mod:some interference, S:activity prevented. Vomiting- Any:present, M:1-2 times/day (d), Mod:\>2/d, S:required intravenous hydration. Diarrhoea- Any:present, M:2-3 loose stools/d, Mod:4-5/d, S:\>=6/d. All reports of fever \>40 degrees C were confirmed as data entry errors.
Time frame: Within 14 days after vaccination
Percentage of Participants With Treatment-Emergent Adverse Events (AEs) or Serious Adverse Events (SAEs)
An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between vaccination and up to 1 month (28 to 42 days) after vaccination that were absent before treatment or that worsened relative to pre-treatment state.
Time frame: Baseline up to 1 Month (28 to 42 days) after vaccination
Percentage of Participants Achieving Serotype-Specific Opsonophagocytic Activity (OPA) Titer With at Least Lower Limit of Quantification (LLOQ) 1 Month After Vaccination
Percentage of participants achieving OPA GMTs with at least LLOQ for 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) determined in blood samples of all participants using microcolony OPA assay. Exact 2-sided CI based on observed proportion of participants. LLOQ for each serotype: 1=1:18, 3=1:12, 4=1:21, 5=1:29, 6A=1:37, 6B=1:43, 7F=1:210, 9V=1:345, 14=1:35, 18C=1:31, 19A=1:18, 19F=1:48, 23F=1:13.
Time frame: One month (28 to 42 days) after vaccination
Serotype-Specific Pneumococcal Opsonophagocytic Activity (OPA) Geometric Mean Fold Rise (GMFR) From Pre-Vaccination to 1 Month Post-Vaccination
Geometric mean fold rises (GMFRs) for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from pre-vaccination to 1 month post-vaccination were computed using the logarithmically transformed assay results. CIs for GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
Time frame: Pre-vaccination to 1 month (28 to 42 days) after vaccination
| Milestone | 13vPnC, Cohort 1 | 13vPnC, Cohort 2 |
|---|---|---|
| Started | 162 | 162 |
| Vaccinated | 162 | 161 |
| Completed | 160 | 161 |
| Not completed | 2 | 1 |
| Withdrew: Withdrawal by subject | 2 | 1 |
Serotype-specific OPA GMTs for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) were determined in the blood samples of all the participants using a quantitative functional OPA assay. Confidence intervals (CIs) for GMT are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers. Individual OPA assay values below the assay LLOQ (lower limit of quantification) were set at a titer of 0.5\*limit of detection (LOD \[8\]) = (titer of 4) for the purpose of calculating the OPA GMT.
| titer | 13vPnC, Cohort 1 | 13vPnC, Cohort 2 |
|---|---|---|
| 1 | 120 (92.3 to 155.3) | 84 (62.8 to 112.5) |
| 3 | 88 (72.4 to 106.9) | 89 (70.8 to 111.5) |
| 4 | 1729 (1377.6 to 2170.9) | 1209 (977.1 to 1495.9) |
| 5 | 288 (208.6 to 398.3) | 285 (208.7 to 388.9) |
| 6A | 3380 (2732.9 to 4179.6) | 3343 (2625.2 to 4256.6) |
| 6B | 3982 (3273.2 to 4845.0) | 3384 (2708.6 to 4227.2) |
| 7F | 3130 (2660.9 to 3681.4) | 1929 (1564.7 to 2378.1) |
| 9V | 2416 (1901.0 to 3071.4) | 1402 (1030.8 to 1906.8) |
| 14 | 1569 (1267.9 to 1940.3) | 1316 (1068.9 to 1619.3) |
| 18C | 3063 (2405.9 to 3900.7) | 2197 (1727.2 to 2794.8) |
| 19A | 1542 (1257.9 to 1889.0) | 1196 (990.6 to 1443.1) |
| 19F | 1104 (828.1 to 1473.1) | 1188 (905.0 to 1558.6) |
| 23F | 879 (650.3 to 1187.7) | 930 (667.1 to 1296.2) |
Local reactions reported using an electronic diary. Redness and Swelling scaled as Any (redness present or swelling present), Mild (2.5 to 5.0 centimeters \[cm\]), Moderate (5.1 to 10.0 cm), Severe (\>10 cm). Pain at injection site scaled as Any (pain present), Mild (does not interfere with activity), Moderate (interferes with activity), Severe (prevents daily activity).
| percentage of participants | 13vPnC, Cohort 1 | 13vPnC, Cohort 2 |
|---|---|---|
| Redness: Any (n=125, 120) | 14.4 (8.8 to 21.8) | 15.8 (9.8 to 23.6) |
| Redness: Mild (n=124, 120) | 9.7 (5.1 to 16.3) | 13.3 (7.8 to 20.7) |
| Redness: Moderate (n=125, 115) | 8.8 (4.5 to 15.2) | 7.0 (3.1 to 13.2) |
| Redness: Severe (n=125, 112) | 2.4 (0.5 to 6.9) | 0.0 (0.0 to 3.2) |
| Swelling: Any (n=130, 120) | 21.5 (14.8 to 29.6) | 13.3 (7.8 to 20.7) |
| Swelling: Mild (n=127, 120) | 18.1 (11.8 to 25.9) | 11.7 (6.5 to 18.8) |
| Swelling: Moderate (n=127, 114) | 8.7 (4.4 to 15.0) | 4.4 (1.4 to 9.9) |
| Swelling: Severe (n=125, 113) | 2.4 (0.5 to 6.9) | 0.9 (0.0 to 4.8) |
| Pain at injection site: Any (n=151, 137) | 75.5 (67.8 to 82.1) | 60.6 (51.9 to 68.8) |
| Pain at injection site: Mild (n=151, 136) | 74.2 (66.4 to 80.9) | 60.3 (51.6 to 68.6) |
| Pain at injection site: Moderate (n=130, 117) | 21.5 (14.8 to 29.6) | 8.5 (4.2 to 15.2) |
| Pain at injection site: Severe (n=125, 113) | 3.2 (0.9 to 8.0) | 3.5 (1.0 to 8.8) |
Systemic events reported using electronic diary. Fever-Any:\>=38 degrees Celsius (C), Mild (M):\>=38 to \<38.5 degrees C, Moderate(Mod):\>=38.5 to \<39 degrees C, Severe (S):\>=39 to \<=40 degrees C, Potentially life threatening:\>40 degrees C. Headache, fatigue, muscle pain, joint pain- Any: present, M:did not interfere with activity, Mod:some interference, S:activity prevented. Vomiting- Any:present, M:1-2 times/day (d), Mod:\>2/d, S:required intravenous hydration. Diarrhoea- Any:present, M:2-3 loose stools/d, Mod:4-5/d, S:\>=6/d. All reports of fever \>40 degrees C were confirmed as data entry errors.
| percentage of participants | 13vPnC, Cohort 1 | 13vPnC, Cohort 2 |
|---|---|---|
| Fever: Any (n=126, 118) | 2.4 (0.5 to 6.8) | 10.2 (5.4 to 17.1) |
| Fever: Mild (n=126, 113) | 1.6 (0.2 to 5.6) | 3.5 (1.0 to 8.8) |
| Fever: Moderate (n=125, 113) | 0.8 (0.0 to 4.4) | 1.8 (0.2 to 6.2) |
| Fever: Severe (n=124, 113) | 0.8 (0.0 to 4.4) | 1.8 (0.2 to 6.2) |
| Fever: Potentially life threatening (n=124, 116) | 0.0 (0.0 to 2.9) | 4.3 (1.4 to 9.8) |
| Fatigue: Any (n=144, 132) | 47.2 (38.9 to 55.7) | 38.6 (30.3 to 47.5) |
| Fatigue: Mild (n=142, 130) | 39.4 (31.3 to 48.0) | 36.2 (27.9 to 45.0) |
| Fatigue: Moderate (n=134, 125) | 26.9 (19.6 to 35.2) | 20.0 (13.4 to 28.1) |
| Fatigue: Severe (n=126, 113) | 6.3 (2.8 to 12.1) | 5.3 (2.0 to 11.2) |
| Headache: Any (n=140, 129) | 44.3 (35.9 to 52.9) | 32.6 (24.6 to 41.4) |
| Headache: Mild (n=140, 128) | 39.3 (31.1 to 47.9) | 30.5 (22.6 to 39.2) |
| Headache: Moderate (n=129, 119) | 18.6 (12.3 to 26.4) | 16.0 (9.9 to 23.8) |
| Headache: Severe (n=126, 115) | 4.0 (1.3 to 9.0) | 5.2 (1.9 to 11.0) |
| Vomiting: Any (n=125, 113) | 4.0 (1.3 to 9.1) | 1.8 (0.2 to 6.2) |
| Vomiting: Mild (n=125, 113) | 3.2 (0.9 to 8.0) | 1.8 (0.2 to 6.2) |
| Vomiting: Moderate (n=124, 113) | 1.6 (0.2 to 5.7) | 0.9 (0.0 to 4.8) |
| Vomiting: Severe (n=124, 112) | 0.0 (0.0 to 2.9) | 0.0 (0.0 to 3.2) |
| Diarrhea: Any (n=134, 120) | 26.1 (18.9 to 34.4) | 15.0 (9.1 to 22.7) |
| Diarrhea: Mild (n=129, 120) | 23.3 (16.3 to 31.5) | 14.2 (8.5 to 21.7) |
| Diarrhea: Moderate (n=129, 113) | 6.2 (2.7 to 11.9) | 1.8 (0.2 to 6.2) |
| Diarrhea: Severe (n=125, 112) | 0.8 (0.0 to 4.4) | 0.9 (0.0 to 4.9) |
| Muscle pain: Any (n=147, 132) | 60.5 (52.2 to 68.5) | 43.9 (35.3 to 52.8) |
| Muscle pain: Mild (n=146, 129) | 59.6 (51.2 to 67.6) | 40.3 (31.8 to 49.3) |
| Muscle pain: Moderate (n=132, 123) | 23.5 (16.5 to 31.6) | 19.5 (12.9 to 27.6) |
| Muscle pain: Severe (n=125, 116) | 5.6 (2.3 to 11.2) | 6.0 (2.5 to 12.0) |
| Joint pain: Any (n=139, 129) | 35.3 (27.3 to 43.8) | 33.3 (25.3 to 42.2) |
| Joint pain: Mild (n=137, 127) | 30.7 (23.1 to 39.1) | 29.9 (22.1 to 38.7) |
| Joint pain: Moderate (n=130, 123) | 13.1 (7.8 to 20.1) | 17.1 (10.9 to 24.9) |
| Joint pain: Severe (n=125, 116) | 4.0 (1.3 to 9.1) | 5.2 (1.9 to 10.9) |
| Use of medication to treat fever (n=129, 118) | 11.6 (6.7 to 18.5) | 13.6 (8.0 to 21.1) |
| Use of medication to treat pain (n=130, 121) | 13.8 (8.4 to 21.0) | 12.4 (7.1 to 19.6) |
An AE was any untoward medical occurrence in a participant who received vaccine without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial/prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent are events between vaccination and up to 1 month (28 to 42 days) after vaccination that were absent before treatment or that worsened relative to pre-treatment state.
| percentage of participants | 13vPnC, Cohort 1 | 13vPnC, Cohort 2 |
|---|---|---|
| AEs | 11.1 (6.7 to 17.0) | 6.2 (3.0 to 11.1) |
| SAEs | 0.0 (0.0 to 2.3) | 1.2 (0.2 to 4.4) |
Percentage of participants achieving OPA GMTs with at least LLOQ for 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) determined in blood samples of all participants using microcolony OPA assay. Exact 2-sided CI based on observed proportion of participants. LLOQ for each serotype: 1=1:18, 3=1:12, 4=1:21, 5=1:29, 6A=1:37, 6B=1:43, 7F=1:210, 9V=1:345, 14=1:35, 18C=1:31, 19A=1:18, 19F=1:48, 23F=1:13.
| percentage of participants | 13vPnC, Cohort 1 | 13vPnC, Cohort 2 |
|---|---|---|
| 1 | 90.3 (84.5 to 94.5) | 81.0 (74.0 to 86.8) |
| 3 | 94.8 (90.0 to 97.7) | 90.1 (84.2 to 94.4) |
| 4 | 97.4 (93.4 to 99.3) | 98.7 (95.3 to 99.8) |
| 5 | 89.2 (83.0 to 93.7) | 90.8 (85.0 to 94.9) |
| 6A | 98.7 (95.4 to 99.8) | 98.1 (94.6 to 99.6) |
| 6B | 99.4 (96.4 to 100.0) | 98.7 (95.5 to 99.8) |
| 7F | 99.4 (96.5 to 100.0) | 97.5 (93.6 to 99.3) |
| 9V | 96.8 (92.6 to 98.9) | 92.3 (86.9 to 95.9) |
| 14 | 98.1 (94.4 to 99.6) | 98.1 (94.5 to 99.6) |
| 18C | 98.1 (94.4 to 99.6) | 98.7 (95.4 to 99.8) |
| 19A | 99.3 (96.4 to 100.0) | 99.4 (96.5 to 100.0) |
| 19F | 95.4 (90.7 to 98.1) | 96.0 (91.5 to 98.5) |
| 23F | 94.2 (89.2 to 97.3) | 91.7 (86.2 to 95.5) |
Geometric mean fold rises (GMFRs) for the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F) from pre-vaccination to 1 month post-vaccination were computed using the logarithmically transformed assay results. CIs for GMFR are back transformations of a CI based on the Student t distribution for the mean logarithm of the titers.
| fold rise | 13vPnC, Cohort 1 | 13vPnC, Cohort 2 |
|---|---|---|
| 1 | 21.3 (16.17 to 28.16) | 11.7 (8.70 to 15.82) |
| 3 | 12.5 (9.77 to 16.05) | 7.8 (6.03 to 10.02) |
| 4 | 57.7 (36.40 to 91.36) | 19.9 (13.23 to 29.88) |
| 5 | 37.3 (26.06 to 53.47) | 26.2 (18.74 to 36.72) |
| 6A | 62.3 (39.00 to 99.36) | 28.7 (19.76 to 41.70) |
| 6B | 18.1 (11.61 to 28.15) | 9.4 (6.61 to 13.45) |
| 7F | 43.2 (26.94 to 69.17) | 15.5 (10.05 to 23.80) |
| 9V | 8.8 (5.72 to 13.43) | 7.2 (4.72 to 10.98) |
| 14 | 5.3 (3.73 to 7.56) | 3.4 (2.58 to 4.56) |
| 18C | 44.3 (28.19 to 69.51) | 13.9 (9.21 to 21.09) |
| 19A | 30.0 (21.19 to 42.50) | 11.2 (7.99 to 15.69) |
| 19F | 42.8 (28.33 to 64.67) | 20.8 (13.38 to 32.29) |
| 23F | 63.6 (43.16 to 93.75) | 35.8 (24.16 to 52.95) |
Collected over Adverse events: recorded from signing of informed consent form to 28-42 days post 13vPnC. Participants recorded pre-specified AEs in electronic diary: local reactions and systemic events from Day 1 to 14 post 13vPnC.. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 13vPnC, Cohort 1 | — | 0/162 (0%) | 119/162 (73.5%) |
| 13vPnC, Cohort 2 | — | 2/161 (1.2%) | 88/161 (54.7%) |
| Event | 13vPnC, Cohort 1 | 13vPnC, Cohort 2 |
|---|---|---|
| Gastric ulcerGastrointestinal disorders | 0/162 | 1/161 |
| GastritisGastrointestinal disorders | 0/162 | 1/161 |
| Benign prostatic hyperplasiaReproductive system and breast disorders | 0/162 | 1/161 |
| Event | 13vPnC, Cohort 1 | 13vPnC, Cohort 2 |
|---|---|---|
| Pain at injection site AnySkin and subcutaneous tissue disorders | 114/151 | 83/137 |
| Pain at injection site MildSkin and subcutaneous tissue disorders | 112/151 | 82/136 |
| Muscle pain AnyGeneral disorders | 89/147 | 58/132 |
| Muscle pain MildGeneral disorders | 87/146 | 52/129 |
| Fatigue AnyGeneral disorders | 68/144 | 51/132 |
| Headache AnyGeneral disorders | 62/140 | 42/129 |
| Fatigue MildGeneral disorders | 56/142 | 47/130 |
| Headache MildGeneral disorders | 55/140 | 39/129 |
| Joint pain AnyGeneral disorders | 49/139 | 43/129 |
| Joint pain MildGeneral disorders | 42/137 | 38/127 |
| Age Continuous(years) | 13vPnC, Cohort 1 | 13vPnC, Cohort 2 | Total |
|---|---|---|---|
| Mean | 55.7 ± 4.0 | 73.4 ± 5.8 | 64.5 ± 10.1 |
| Sex: Female, Male(Participants) | 13vPnC, Cohort 1 | 13vPnC, Cohort 2 | Total |
|---|---|---|---|
| Female | 96 | 84 | 180 |
| Male | 66 | 77 | 143 |
The record gives a start of Jul 2011, a primary completion of Dec 2011 and a completion of Dec 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2013, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: 13-valent pneumococcal vaccine